Main Article Content
Myocardial fibrosis is a pathological condition that responsible for initiation of heart failure. Neurohormonal endogen, angiotensin II, has a potential role to activate endothelin I, TGF-Î²1, myocardial fibroblast, extracelullar matrix deposition, structural changes and decreasing of cardiac function. Fibrotic process is also influenced by PPAR Î³. Telmisartan has a potential effect to inactivate angiotensinergic system and to activate PPAR Î³. It is expected that telmisartan has optimal effect to protect myocardial fibrosis. To know the role of variation dose of telmisartan to decrease collagen type 1 fraction volume in cardiac tissue of Wistar rats.
Ten-week-old male Wistar Rat (n = 30) were randomized into five groups, and each group consisted of 6 rats. Group 1 : negative control. Group 2 : rats were induced by intake Nacl 8% doses 2% body weight for eight weeks. Group 3 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 3 mg/kgBB for eight weeks. Group 4 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 6 mg/kgBB for eight weeks. Group 5 : rats were induced by intake Nacl 8% doses 2% body weight and telmisartan 12 mg/kgBB for eight weeks. Collagen volume fraction was assessed by immunohistochemistry and ImageJ program. ANOVA test followed pos hoc test was used to analyzed each variable.
Collagen volume fraction significantly decreased in group 3, 4 and 5 compared in group 2. Telmisartan decreases collagen type 1 volume fraction of myocardial tissue .
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.